drugset / Trial / NCT00108186
Celecoxib Treatment for Lung Cancer
Phase 1
Withdrawn
US Department of Veterans Affairs
City of Hope Medical Center · collabUniversity of California, Los Angeles · collab
Non-randomizedSingle-groupOpen-labelBasic science
Summary
This proposal evaluates cyclooxygenase 2 (COX-2) inhibition as a means to decrease T regulatory cell activities and thus augment immune responses against lung cancer. The broad goal focuses on understanding how COX-2 expression regulates the malignant phenotype in non small cell lung cancer in an effort to foster an informed approach for the use of COX-2 inhibitors in prevention and therapy for lung cancer.
Timeline
- Start
- 2004-10
- Primary completion
- 2010-06
- Completion
- 2011-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Celecoxib | Other / unclassified | 200 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 400 mg | Oral |
| Subject | Celecoxib | Other / unclassified | 600 mg | Oral |